X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare with J.B.Chemicals - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs J.B.CHEMICALS - Comparison Results

J.B.CHEMICALS 
   Change

JB Chemicals and Pharmaceuticals Limited (JBCPL), the flagship of the Unique Group, is one of the India's leading transnational pharmaceutical company. The company has 11 manufacturing facilities at four locations in India (Belapur, Ankleshwar, Panol... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES J.B.CHEMICALS ALKEM LABORATORIES/
J.B.CHEMICALS
 
P/E (TTM) x - 14.7 - View Chart
P/BV x 7.4 2.3 318.7% View Chart
Dividend Yield % 0.6 0.2 350.9%  

Financials

 ALKEM LABORATORIES   J.B.CHEMICALS
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
J.B.CHEMICALS
Mar-16
ALKEM LABORATORIES/
J.B.CHEMICALS
5-Yr Chart
Click to enlarge
High Rs1,589318 499.5%   
Low Rs1,232200 617.5%   
Sales per share (Unadj.) Rs417.5148.0 282.1%  
Earnings per share (Unadj.) Rs56.319.1 295.0%  
Cash flow per share (Unadj.) Rs64.723.9 270.2%  
Dividends per share (Unadj.) Rs12.700.50 2,540.0%  
Dividend yield (eoy) %0.90.2 466.0%  
Book value per share (Unadj.) Rs292.9128.9 227.2%  
Shares outstanding (eoy) m119.5784.82 141.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.41.7 193.2%   
Avg P/E ratio x25.113.6 184.8%  
P/CF ratio (eoy) x21.810.8 201.7%  
Price / Book Value ratio x4.82.0 239.9%  
Dividend payout %22.62.6 861.1%   
Avg Mkt Cap Rs m168,65321,951 768.3%   
No. of employees `000NA2.7 0.0%   
Total wages/salary Rs m9,1711,841 498.1%   
Avg. sales/employee Rs ThNM4,590.9-  
Avg. wages/employee Rs ThNM673.4-  
Avg. net profit/employee Rs ThNM592.1-  
INCOME DATA
Net Sales Rs m49,91512,551 397.7%  
Other income Rs m1,645542 303.7%   
Total revenues Rs m51,56113,093 393.8%   
Gross profit Rs m8,4822,055 412.8%  
Depreciation Rs m1,006412 243.9%   
Interest Rs m67196 700.7%   
Profit before tax Rs m8,4512,088 404.7%   
Minority Interest Rs m-1140 28,450.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,606469 342.4%   
Profit after tax Rs m6,7311,619 415.8%  
Gross profit margin %17.016.4 103.8%  
Effective tax rate %19.022.5 84.6%   
Net profit margin %13.512.9 104.6%  
BALANCE SHEET DATA
Current assets Rs m27,0627,778 347.9%   
Current liabilities Rs m15,3244,358 351.6%   
Net working cap to sales %23.527.2 86.3%  
Current ratio x1.81.8 99.0%  
Inventory Days Days6755 121.7%  
Debtors Days Days4180 51.6%  
Net fixed assets Rs m12,6105,713 220.7%   
Share capital Rs m239170 141.0%   
"Free" reserves Rs m34,49010,547 327.0%   
Net worth Rs m35,02710,937 320.2%   
Long term debt Rs m1,2120-   
Total assets Rs m54,38715,574 349.2%  
Interest coverage x13.622.8 59.6%   
Debt to equity ratio x00-  
Sales to assets ratio x0.90.8 113.9%   
Return on assets %13.611.0 123.6%  
Return on equity %19.214.8 129.8%  
Return on capital %24.920.0 124.5%  
Exports to sales %12.948.7 26.6%   
Imports to sales %3.17.1 43.6%   
Exports (fob) Rs m6,4616,115 105.7%   
Imports (cif) Rs m1,540889 173.3%   
Fx inflow Rs m6,5636,169 106.4%   
Fx outflow Rs m3,0121,285 234.4%   
Net fx Rs m3,5524,884 72.7%   
CASH FLOW
From Operations Rs m7,2591,397 519.7%  
From Investments Rs m1,864-320 -582.0%  
From Financial Activity Rs m-9,273-1,196 775.4%  
Net Cashflow Rs m-150-102 146.6%  

Share Holding

Indian Promoters % 66.9 55.4 120.8%  
Foreign collaborators % 0.0 0.3 -  
Indian inst/Mut Fund % 33.1 3.4 976.4%  
FIIs % 0.0 3.9 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 37.0 -  
Shareholders   68,381 30,437 224.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   SUN PHARMA  DR. REDDYS LAB  GSK PHARMA  UNICHEM LAB  MERCK LTD  

Compare ALKEM LABORATORIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Weak Start to the Week; PSU & Metal Stocks Fall(Closing)

Indian share markets continued to witness selling pressure in the afternoon session as benchmark Sensex slipped below the 34,000-mark.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Feb 19, 2018 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 5-YR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS